ClinicalTrials.gg
RecruitingNCT06564857ROCVIDEOUpdated Sep 21, 2026

Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation

A Phase 4 interventional study of Remifentanil and Rocuronium in Tracheal Intubation, Video Laryngoscopy and Remifentanil, sponsored by Nordsjaellands Hospital. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Nordsjaellands Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,684
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Globally, we are approaching 1 million surgical procedures each day. Tracheal intubation is the mainstay of securing the patient's airway and breathing during general anaesthesia. Approximately 100.000 tracheal intubations are performed annually in Denmark. Airway management remains the primary reason for anaesthesia-related morbidity and mortality. It has been traditionally accepted that best tracheal intubation conditions are obtained by paralysing the patient's muscles, including vocal cords, using a neuromuscular blocking agent (NMBA) such as rocuronium. However, using NBMA may increase the risk of pulmonary complications, intra-operative awareness, in which the patient is paralysed but awake during surgery, anaphylaxis, and re-intubation. In addition, there is a risk of residual neuromuscular blockade postoperatively. In the US, prolonged ventilation and unplanned intubation are the top two most costly perioperative complications. An alternative to NMBA is a large dose of opioids to depress laryngeal reflexes during intubation. The most commonly used non-NMBA modality includes bolus administration of remifentanil. However, remifentanil may cause bradycardia and hypotension. Even short periods of hypotension have been shown to increase the risk of myocardial injury and other serious adverse events such as renal failure, delirium, and even mortality.

Evidence also indicates that intubation conditions using only opioids to facilitate intubation, including remifentanil, are inferior to NMBA. However, these trials are underpowered to assess effects on patient-important outcomes and are mostly at high risk of bias. A recent trial has suggested that remifentanil intubation conditions may not be very different. Almost all existing research comparing NMBA to opioids has focused on intubation conditions for direct laryngoscopy using a conventional Macintosh laryngoscopy blade. In recent years, the implementation and availability of the video laryngoscope have grown exponentially and become universal. The video laryngoscope has vastly improved the ease of tracheal intubation, and the number of failed intubations has decreased by two-thirds in Denmark, where a rapid implementation of the video laryngoscope took place. However, limited evidence exists on whether NMBA improves intubation conditions compared to remifentanil when performing video laryngoscope-assisted tracheal intubation.

02

Conditions studied

  • Tracheal Intubation
  • Video Laryngoscopy
  • Remifentanil
  • Rocuronium
03

In context

Lead sponsor

Nordsjaellands Hospital is the lead sponsor of 89 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years
  • Undergoing general anaesthesia requiring oro-tracheal intubation
  • Absence of indication for rapid sequence induction
  • (ASA) physical status score I - III

Exclusion criteria

Exclusion Criteria:

  • Known allergies or to rocuronium (e.g. neuromuscular disease) or remifentanil
  • Awake intubation
  • Double-lumen endotracheal tube
  • Oral, pharyngeal, and laryngeal surgery
  • Surgical contraindication for NMBAs (e.g. use of nerve stimulator)
  • Patients who are pregnant or breastfeeding
  • Patients who do not understand Danish or are unable to give
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,684 participants (estimated)

Study arms

  • Experimental
    REMI-arm

    Bolus of remifentanil at anaesthesia induction

    Drug: Remifentanil

  • Active comparator
    ROCU-arm

    Bolus of rocuronium at anaesthesia induction

    Drug: Rocuronium

Interventions

  • Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction

    Also known as: Remifentanil 5 mg diluted in 100 ml saline, which corresponds to Remifentanil 50 micrograms/ml

  • Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction

    Also known as: Rocuronium 10 mg/ml

06

What researchers measure

Primary outcomes

  1. Proportion of participants with one or more intubation or anaesthesia related adverse events

    Early (\< 10 min): Cardiac arrest; anaphylaxis; pulmonary aspiration of gastric content; serious traumatic airway injury; desaturation (SAT \< 90%); major hemodynamic instability (MAP \< 50, new onset bradycardia \< 40 beats/min); or sustained new arrhythmia (causing hemodynamic instability or requiring intervention). Late (\< 24 h): Death; brain damage including stroke; acute myocardial infarction; ICU admission; re-intubation; respiratory failure (oxygen demand \> 5 l/min or requiring interventions aside from oxygen therapy); intraoperative awareness; pneumonia; dental injury; sore throat; or hoarseness.

    Time frame: 0 minutes to 24 hours after administration of drugs for intubation

  2. Proportion of participants with failed first-pass intubation

    Defined as failed tracheal tube delivery after the first attempt of introduction of the video laryngoscope into the patient's mouth. Tracheal tube delivery is defined as failed when the tube is retracted out of the patient's mouth, OR the video laryngoscope has to be retracted out of the patient's mouth, OR there is a shift in intubation equipment OR a change in the person performing the intubation management OR the intubation is abandoned.

    Time frame: Tracheal intubation is performed 2 minutes after administration of rocuronium or remifentanil.

Secondary outcomes

  1. Patient satisfaction score

    The patient's experience of the treatment using a numeric rating scale (NRS 0 - 10 (0 = very dissatisfied; 10 = very satisfied))

    Time frame: 24 hours after administration of drugs for intubation

  2. Proportion of participants with one or more serious adverse events 0-7 days

    Defined as: respiratory failure, major adverse cardiac (in-hospital all-cause death, acute myocardial infarction (AMI) both acute ST elevation MI and non-ST elevation MI, complete heart block, cardiogenic shock, cardiac arrhythmia and cardiac arrest), pneumonia, acute kidney injury, admission to ICU and cerebrovascular event (ischemic stroke including transient cerebral ischemia).

    Time frame: 0 minutes to 7 days after administration of drugs for intubation

  3. Lengths of stay at the Post-Anaesthesia Care Unit.

    Minutes the patient is at the Post-Anaesthesia Care Unit.

    Time frame: 0-48 hours postoperatively

Other outcomes

  1. Proportion of participants with failed intubation

    The intubation is abandoned

    Time frame: 2 to 20 minutes after administration of drugs for intubation

  2. Number of intubation attempts

    The first attempt is defined as an attempt (successful or not) at tracheal tube delivery after the first introduction of the video laryngoscope into the patient's mouth. Additionally attempts are defined as: when the tube has to be re-introduced into the patient's mouth, OR the videolaryngoscopy has to be re-introduced into the patient mouth, OR there is a shift in intubation equipment OR a change in the person performing the intubation management

    Time frame: 2 to 20 minutes after administration of drugs for intubation

  3. Vocal cords position at first intubation attempt

    Categorised as closed, intermediate or open

    Time frame: 2 to 20 minutes after administration of drugs for intubation

  4. Proportion of participants with need for rescue medication or airway management

    Rescue medication is defined as: An additional bolus of neuromuscular blocking agents, or bolus of opioid or propofol or other anesthetics according to the discretion of the attending anaesthesiologist in order to solve insufficient airway management conditions.

    Time frame: 2 to 20 minutes after administration of drugs for intubation

  5. Proportion of participants with anaesthesia induction related grave desaturation

    SAT \< 80%

    Time frame: 0 to 10 minutes after administration of drugs for intubation

  6. Proportion of participants in need of vasoactive or chronotropic substances after induction

    Defined as any vasoactive substance, e.g. epinephrine, noradrenaline, phenylephrine, ephedrine administrated as a response to severe hypotension or bradycardia after induction.

    Time frame: 0 to 10 minutes after administration of drugs for intubation

  7. Individual components of the composite outcomes "Proportion of participants with one or more intubation or anaesthesia related adverse events" and "Proportion of participants with one or more serious adverse events 0-7 days"

    As stated in the relevant outcome descriptions

    Time frame: 0 minutes to 7 days after administration of drugs for intubation

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Ipsen EO, Lundstrom LH, Lodenius A, Fisker G, Hovind MF, Nielsen CL, Oskarsdottir H, Strom C, Rosenstock CV, Madsen KPD, Wichmann S, Afshari A, Andersen JH, Nedergaard HK, Bill L, Cronhjort M, Mathiesen O, Jakobsen JC, Vested M, Norskov AK. Remifentanil Versus Rocuronium for Optimising Video Laryngoscopy Assisted Tracheal Intubation-The ROCVIDEO Trial Protocol. Acta Anaesthesiol Scand. 2026 Jul;70(6):e70277. doi: 10.1111/aas.70277. PubMed 42304626 ↗

Individual participant data

Plan to share: Yes — Anonymised data will be made available upon reasonable request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The protocol is submitted prior to first randomisation. A comprehensive statistical analysis plan, including pre-specified subgroup analysis will be published before the final participant is enrolled. Other material will be made available \<12 months after trial cessation

Access criteria: Anonymised data will be made available upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Aug 21, 2024
StartActual
Nov 17, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 8, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564857
Lead sponsor
Nordsjaellands Hospital
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Nov 17, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 8, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Anders K Nørskov, PhD
Contact
anders.kehlet.noerskov@regionh.dk
48292510 ext. +45
Lars H Lundstrøm, PhD
Contact
lars.hyldborg.lundstroem.02@regionh.dk
48296512 ext. +45
Anders K Nørskov, PhD
principal investigator · Department of Anaesthesia, Nordsjællands Hospital - Hillerød, Denmark
Matias Vested, PhD
principal investigator · Department of Anaesthesia Centre of Head and Orthopedics Rigshospitalet, University of Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remifentanil

Start the discussion